- Home
- DQ vs GYRE Comparison
DQ vs GYRE Comparison
Compare DQ & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DQ
- GYRE
- Stock Information
- Founded
- DQ 2006
- GYRE 2002
- Country
- DQ China
- GYRE United States
- Employees
- DQ N/A
- GYRE N/A
- Industry
- DQ Semiconductors
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- DQ Technology
- GYRE Health Care
- Exchange
- DQ Nasdaq
- GYRE Nasdaq
- Market Cap
- DQ 970.3M
- GYRE 897.1M
- IPO Year
- DQ 2010
- GYRE N/A
- Fundamental
- Price
- DQ $20.02
- GYRE $7.49
- Analyst Decision
- DQ Buy
- GYRE
- Analyst Count
- DQ 6
- GYRE 0
- Target Price
- DQ $23.91
- GYRE N/A
- AVG Volume (30 Days)
- DQ 1.3M
- GYRE 189.9K
- Earning Date
- DQ 08-25-2025
- GYRE 08-12-2025
- Dividend Yield
- DQ N/A
- GYRE N/A
- EPS Growth
- DQ N/A
- GYRE N/A
- EPS
- DQ N/A
- GYRE 0.02
- Revenue
- DQ $737,683,000.00
- GYRE $100,643,000.00
- Revenue This Year
- DQ N/A
- GYRE $21.04
- Revenue Next Year
- DQ $93.91
- GYRE $89.64
- P/E Ratio
- DQ N/A
- GYRE $93.64
- Revenue Growth
- DQ N/A
- GYRE N/A
- 52 Week Low
- DQ $12.41
- GYRE $6.11
- 52 Week High
- DQ $30.85
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- DQ 72.79
- GYRE 42.81
- Support Level
- DQ $18.12
- GYRE $7.49
- Resistance Level
- DQ $21.00
- GYRE $7.80
- Average True Range (ATR)
- DQ 0.97
- GYRE 0.48
- MACD
- DQ 0.53
- GYRE 0.07
- Stochastic Oscillator
- DQ 86.65
- GYRE 40.48
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.